|Bid||41.49 x 1400|
|Ask||41.50 x 900|
|Day's Range||41.36 - 41.52|
|52 Week Range||30.67 - 60.81|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||1.87|
|Forward Dividend & Yield||2.70 (6.50%)|
|1y Target Est||44.46|
BAT, Philip Morris International Inc. and a local unit of Japan Tobacco Inc. are defendants in lawsuits by Canada’s 10 provinces that want to recoup health-care costs linked to the effects of smoking, a move reminiscent of the U.S. in the 1990s. The first of these cases, some of which date back almost two decades, is scheduled to come to trial this year.
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
British American Tobacco PLC put one of Canada’s top cigarette distributors into bankruptcy protection in the U.S. after that subsidiary, sued by Quebec smokers in 1998 for hiding health risks, was ordered to pay 9.2 billion Canadian dollars (US$6.9 billion). Officials who put Imperial Tobacco Canada Ltd. into chapter 15 protection in U.S. Bankruptcy Court in New York said the move is meant stop creditors from taking the tobacco held at the company’s Ohio and Montana warehouses while it negotiates a payment plan. Tobacco for its cigarettes, grown in Mexico, is stored in those warehouses as part of its importing process.
EU Says UK Parliament Is Titanic Voting for Iceberg to Move Parliamentary democracy may have some power, but it can’t tell parliaments outside of itself what to do. In “ruling out” a no deal Brexit yesterday in a vote, chief Brexit negotiator for the European Union, Michel Barnier, has likened it to the Titanic voting […]The post Market Morning: EU Rolls Eyes At UK, FAA Grounds 737, FDA Smashes E-Cigs, Tesla DeLorean On Deck appeared first on Market Exclusive.
The FDA said it's advancing a vision of a world where combustible cigarettes no longer create or contribute to addiction — and better protecting users from tobacco-related disease and death. What’s Next? The FDA’s overall ambition continues to be designing a policy blueprint for safer tobacco-related products for users. This puts nicotine at the center of regulatory efforts.
British American Tobacco ’s Canadian subsidiary has been granted creditor protection, giving the unit a temporary reprieve after a Quebec court judgment had held the industry liable for a maximum of C$13.6bn ...
“This reinforces our view that investors were premature to assume that Gottlieb’s departure would lead to a lighter regulatory hand over the tobacco industry out of Washington. Separately, BAT said it had put its Canadian subsidiary into insolvency administration. Canada was estimated to contribute about 4 per cent of BAT’s underlying earnings.
U.S. President Donald Trump's administration has tapped National Cancer Institute Director Norman Sharpless to serve as acting commissioner for the Food and Drug Administration, following the resignation of Scott Gottlieb earlier this month. Sharpless, who has led the National Institutes of Health's cancer unit since 2017, will take over following Gottlieb's exit in April, the U.S. Department of Health and Human Services said on Tuesday.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Altria (MO) closes investment deal in Cronos Group. The move is in sync with the company's efforts to expand in the smokeless category.
WINSTON-SALEM, N.C. (AP) — An Ohio manufacturer of electronic cigarettes has accused the R.J. Reynolds Vapor Company of patent infringement.
Investors in Altria Group (NYSE:MO) enjoyed months of steady upside throughout much of last year, only to see the stock fall since November. But on Jan. 24, when the stock bottomed at $43.33 on the day, investors bottom-fishing appear to have started accumulating the stock, ahead of the dividend declaration.Source: Peyri Herrera via Flickr (Modified)Those not holding the stock have until March 22 to be a shareholder of record to earn an 80-cent quarterly dividend. So, what are the pros and cons of buying MO stock now after the stock's 25% bounce from the bottom? Dividend IncomeThe 6.05% dividend yield is a pro for holding Altria stock, especially when the payout ratio is 76% and grew 10.3% over the last five years. Even if political uncertainties questioning the sale of tobacco might damage future sales, the industry has a way of surviving such attacks. Despite Altria, British American Tobacco (NYSE:BTI) and Philip Morris (NYSE:PM) demonstrating its ability to continue on its business, Altria is diversifying its business. Very recently, it made a massive investment in a Canadian cannabis firm.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Indirect Exposure to Growth in Cannabis MarketAltria's C$2.4 billion investment in Cronos Group Inc. (NASDAQ:CRON) gives shareholders an indirect equity exposure to the fast-growing cannabis market. Cronos said that the investment received would support its innovation in cannabinoid innovation. It also lets Cronos create differentiated products and brands of cannabinoid-based products for both the medical and recreational markets. * 7 Stocks That Should Be Worried About a Data Dividend Altria paid a hefty price tag for gaining a quick entry into the cannabis market but it has to do so. If cannabis becomes a substitute for cigarettes or e-cigarettes, Altria would still benefit from the trend through its Cronos investment. Investing in JuulOn Dec. 10, 2018, Altria shuttered its e-cigarette brands and took a charge of around $200 million. 10 days later, it announced a $12.8 billion investment in Juul, in an all-cash deal. Altria's 35% stake is strategically similar to that of the Cronos deal. Instead of starting the business from scratch, it is investing in a popular and well-known product to broaden its business and to gain a partner. Risks in Altria's InvestmentsNow for the cons of investing in Altria.Altria already has a debt/equity of 1.74 times. And investing billions, essentially paying a generous premium in the hot market of both cannabis and e-cigs, comes with some risks. If these companies do not maintain their high growth rates, Altria may have to write-down its investments.Competitors might follow suit by making similar investments, forcing Altria to do even more deals. Its cash balance will fall and the firm may need to raise debt to finance overpriced deals. By then, upset investors will be too late in voting out executives to change the company's strategic direction of acquisition through growth. ValuationAltria is still trading at 20% below its yearly high. 9 of the Wall Street analysts have, on average, a ~10% upside price target at $58 a share (according to Tipranks). With the stock trading at around 14 times earnings, and a long-term EPS growth target of 7% to 9%, the stock's PEG is as low as 1.55 times.Over the last 9 years, from 2009 - 2018, Altria grew adjusted operating income by 5.1% while its adjusted OCI margins expanded by 13.3%. These strong historical numbers suggest that the company will continue to grow all of its businesses. Its big investments in e-cigs and cannabis may pay off in the long-run as these two markets expand. Your TakeawayAltria is actively embracing future opportunities for tobacco harm reduction. Its investment in Juul is evidence that it wants to sell products that do not make its customers unhealthy. With the e-vapor international opportunity at $6 billion in North America and $17 billion internationally, Altria cannot afford to be without an investment in Juul. It also needs to continue to offer innovative tobacco products. The combination of these product streams will diversify Altria's income, which is net positive for its shareholders.Altria stock is not yet back to the $60 - $65 range but it could get there this year if the company demonstrates steady earnings growth.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Blue-Chip Stocks That Will Lose You Money * 7 Cheap Stocks Under $5 That Could Soar * 7 Stocks Under $10 You Shouldn't Buy Compare Brokers The post The Run-Up in Altria Stock Isn't Over Yet appeared first on InvestorPlace.
In a move that has the tobacco industry breathing easier, U.S. Food and Drug Administration Commissioner Scott Gottlieb, a vocal critic of the vaping industry's influence on teen users, is leaving his post. The Department of Health and Human Service said Tuesday that Gottlieb will step down to spend more time with his family -- news that sent tobacco stocks higher. jumped by about 1.5% as soon as news of Gottlieb's departure broke at about 3 p.m. ET, although MO later dropped back to close at $52.88, +0.8% on the day.